Genetic variability in enzymes of metabolic pathways conferring
protection against non-enzymatic glycation versus
diabetes-related morbidity and mortality

J 2014

Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality

TANHÄUSEROVÁ, Veronika; Katarína KURICOVÁ; Lukáš PÁCAL; Vendula BARTÁKOVÁ; Jitka ŘEHOŘOVÁ et al.

Základní údaje

Originální název

Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality

Autoři

TANHÄUSEROVÁ, Veronika; Katarína KURICOVÁ; Lukáš PÁCAL; Vendula BARTÁKOVÁ ; Jitka ŘEHOŘOVÁ; Jan SVOJANOVSKÝ; Jindřich OLŠOVSKÝ; Jana BĚLOBRÁDKOVÁ a Kateřina KAŇKOVÁ

Vydání

Clinical Chemistry and Laboratory Medicine, Berlin, Walter de Gruyter, 2014, 1434-6621

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30105 Physiology

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.707

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/14:00074668

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

advanced glycation end-products; diabetic nephropathy; fructosamine 3-kinase; glyoxalase; pentose phosphate pathway; transketolase

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 1. 2014 10:12, Soňa Böhmová

Anotace

V originále

Background: We hypothesized that genetic variability in genes encoding enzymes metabolizing glycolytic intermediates produced in excess under hyperglycemic conditions [i.e., transketolase ( TKT ), transaldolase, TKT-like protein 1, fructosamine 3-kinase ( FN3K ), glyoxalase 1 and glucose-6-phosphate dehydrogenase] could influence progression of diabetic nephropathy (DN) and diabetesrelated morbidity and mortality. Methods: A total of 19 single nucleotide polymorphisms (SNPs) in six candidate genes were studied in 314 type 2 diabetic subjects with variable stage of kidney disease (normo- and microalbuminuria, proteinuria, end-stage renal disease). SNP selection criteria were based on known functional effect and gene coverage. SNPs were detected using polymerase chain reaction based methods. Subjects were followed up for median of 38 months. Time-to-event analysis considered three end-points: 1) DN progression by at least one stage; 2) major cardiovascular event; and 3) all-cause mortality. Results: We found combined effect of TKT SNP rs11130362 and FN3K SNP rs1056534 on DN progression (p < 0.01). Additionally, TKT rs3736156 alone and also in combination with the previous two SNPs exhibited significant effect on incidence of major cardiovascular events (p < 0.01 and p = 0.01, respectively). Conclusions: Genetic variability in rate-limiting enzymes of pathways proposed to confer hypothetical protection against hyperglycemia might act as an important determinant of hyperglycemia toxicity in long-standing diabetes.

Návaznosti

NT13198, projekt VaV

Název: Pentózový cyklus jako potenciální nový terapeutický cíl v prevenci diabetických komplikací

Investor: Ministerstvo zdravotnictví ČR, Pentózový cyklus jako potenciální nový terapeutický cíl v prevenci diabetických komplikací

Citovat

TANHÄUSEROVÁ, Veronika; Katarína KURICOVÁ; Lukáš PÁCAL; Vendula BARTÁKOVÁ; Jitka ŘEHOŘOVÁ; Jan SVOJANOVSKÝ; Jindřich OLŠOVSKÝ; Jana BĚLOBRÁDKOVÁ a Kateřina KAŇKOVÁ. Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality. Clinical Chemistry and Laboratory Medicine. Berlin: Walter de Gruyter, 2014, roč. 52, č. 1, s. 77-83. ISSN 1434-6621. Dostupné z: https://doi.org/10.1515/cclm-2012-0833.

@article{1092044,
   author = {Tanhäuserová, Veronika and Kuricová, Katarína and Pácal, Lukáš and Bartáková, Vendula and Řehořová, Jitka and Svojanovský, Jan and Olšovský, Jindřich and Bělobrádková, Jana and Kaňková, Kateřina},
   article_location = {Berlin},
   article_number = {1},
   doi = {https://doi.org/10.1515/cclm-2012-0833},
   keywords = {advanced glycation end-products; diabetic nephropathy; fructosamine 3-kinase; glyoxalase; pentose phosphate pathway; transketolase},
   language = {eng},
   issn = {1434-6621},
   journal = {Clinical Chemistry and Laboratory Medicine},
   title = {Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality},
   volume = {52},
   year = {2014}
}

TY  - JOUR
ID  - 1092044
AU  - Tanhäuserová, Veronika - Kuricová, Katarína - Pácal, Lukáš - Bartáková, Vendula - Řehořová, Jitka - Svojanovský, Jan - Olšovský, Jindřich - Bělobrádková, Jana - Kaňková, Kateřina
PY  - 2014
TI  - Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality
JF  - Clinical Chemistry and Laboratory Medicine
VL  - 52
IS  - 1
SP  - 77-83
EP  - 77-83
PB  - Walter de Gruyter
SN  - 14346621
KW  - advanced glycation end-products
KW  - diabetic nephropathy
KW  - fructosamine 3-kinase
KW  - glyoxalase
KW  - pentose phosphate pathway
KW  - transketolase
N2  - Background: We hypothesized that genetic variability in genes encoding enzymes metabolizing glycolytic intermediates produced in excess under hyperglycemic conditions [i.e., transketolase ( TKT ), transaldolase, TKT-like protein 1, fructosamine 3-kinase ( FN3K ), glyoxalase 1 and glucose-6-phosphate dehydrogenase] could influence progression of diabetic nephropathy (DN) and diabetesrelated morbidity and mortality. Methods: A total of 19 single nucleotide polymorphisms (SNPs) in six candidate genes were studied in 314 type 2 diabetic subjects with variable stage of kidney disease (normo- and microalbuminuria, proteinuria, end-stage renal disease). SNP selection criteria were based on known functional effect and gene coverage. SNPs were detected using polymerase chain reaction based methods. Subjects were followed up for median of 38 months. Time-to-event analysis considered three end-points: 1) DN progression by at least one stage; 2) major cardiovascular event; and 3) all-cause mortality. Results: We found combined effect of TKT SNP rs11130362 and FN3K SNP rs1056534 on DN progression (p < 0.01). Additionally, TKT rs3736156 alone and also in combination with the previous two SNPs exhibited significant effect on incidence of major cardiovascular events (p < 0.01 and p = 0.01, respectively). Conclusions: Genetic variability in rate-limiting enzymes of pathways proposed to confer hypothetical protection against hyperglycemia might act as an important determinant of hyperglycemia toxicity in long-standing diabetes.
ER  -

TANHÄUSEROVÁ, Veronika; Katarína KURICOVÁ; Lukáš PÁCAL; Vendula BARTÁKOVÁ; Jitka ŘEHOŘOVÁ; Jan SVOJANOVSKÝ; Jindřich OLŠOVSKÝ; Jana BĚLOBRÁDKOVÁ a Kateřina KAŇKOVÁ. Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality. \textit{Clinical Chemistry and Laboratory Medicine}. Berlin: Walter de Gruyter, 2014, roč.~52, č.~1, s.~77-83. ISSN~1434-6621. Dostupné z: https://doi.org/10.1515/cclm-2012-0833.

Přehled o publikaci